Abstract
The purpose of this American Gastroenterological Association (AGA) Institute Clinical Practice Update was to rapidly review the emerging evidence and provide timely expert recommendations regarding the management of patients with inflammatory bowel disease during the coronavirus disease 2019 pandemic. This expert commentary was commissioned and approved by the AGA Institute Clinical Practice Updates Committee and the AGA Governing Board to provide timely perspective on a topic of high clinical importance to the AGA membership, and underwent internal peer review by the Clinical Practice Updates Committee and external peer review through standard procedures of Gastroenterology.
Keywords:
Coronavirus; Crohn’s Disease; IBD; Immunosuppression; SARS-CoV-2; Ulcerative Colitis.
Copyright © 2020 AGA Institute. Published by Elsevier Inc. All rights reserved.
MeSH terms
-
Anti-Inflammatory Agents / administration & dosage
-
Anti-Inflammatory Agents / adverse effects
-
Betacoronavirus / immunology*
-
Betacoronavirus / isolation & purification
-
Betacoronavirus / pathogenicity
-
COVID-19
-
Coronavirus Infections / diagnosis
-
Coronavirus Infections / epidemiology
-
Coronavirus Infections / immunology
-
Coronavirus Infections / prevention & control*
-
Gastroenterology / organization & administration
-
Gastroenterology / standards*
-
Humans
-
Infection Control / organization & administration
-
Infection Control / standards
-
Inflammatory Bowel Diseases / diagnosis
-
Inflammatory Bowel Diseases / drug therapy*
-
Inflammatory Bowel Diseases / immunology
-
Infusions, Intravenous / standards
-
Pandemics / prevention & control*
-
Pneumonia, Viral / diagnosis
-
Pneumonia, Viral / epidemiology
-
Pneumonia, Viral / immunology
-
Pneumonia, Viral / prevention & control*
-
Practice Guidelines as Topic*
-
Risk Assessment / standards
-
Risk Factors
-
SARS-CoV-2
-
Severity of Illness Index
-
Societies, Medical / standards
-
United States